Minimal Residual Disease-Directed Therapy for Childhood Acute Myeloid Leukemia: Results of the AML02 Multicenter Trial

BACKGROUND: We sought to improve outcome of childhood acute myeloid leukemia (AML) by applying risk-directed therapy based on the genetic abnormalities of the leukemic cells and measurements of minimal residual disease (MRD) as determined by flow cytometry during treatment. METHODS: From October 13,...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Rubnitz, Jeffrey E., Inaba, Hiroto, Dahl, Gary, Ribeiro, Raul C., Bowman, W. Paul, Taub, Jeffrey, Pounds, Stanley, Razzouk, Bassem I, Lacayo, Norman J., Cao, Xueyuan, Meshinchi, Soheil, Degar, Barbara, Airewele, Gladstone, Raimondi, Susana C., Onciu, Mihaela, Coustan-Smith, Elaine, Downing, James R., Leung, Wing, Pui, Ching-Hon, Campana, Dario
Format: Artigo
Jezik:Inglês
Izdano: 2010
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3171799/
https://ncbi.nlm.nih.gov/pubmed/20451454
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(10)70090-5
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items